

RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

COMMUNICATION

Copper-catalyzed intramolecular dehydrogenative cyclization: direct access to sensitive formyl-substituted imidazo[1,2-*a*]pyridines

Cite this: DOI: 10.1039/x0xx00000x

Li-Hai Zhai,^{a,b} Li-Hong Guo^b, Bai-Wang Sun^{*a}Received 00th January 2012,
Accepted 00th January 2012


DOI: 10.1039/x0xx00000x

www.rsc.org/

A direct method for the synthesis of formyl-substituted imidazo[1,2-*a*]pyridines was achieved easily from cyclization of aminopyridines and cinnamaldehydes via copper catalysis. This oxidative cyclization process involved direct C-H bond functionalization, C-C/C-N bonds formation. In this transformation, the sensitive aldehyde group was preserved under oxidant condition.

Substituted imidazo[1,2-*a*]pyridines, as attracting structural motifs, are found in natural products and organic chemistry with strong bioactivity profiles and interesting structural properties.¹ In particular, They are known to be crucial synthetic precursors to construct a wide range of biologically active compounds in medicinal chemistry,² and drug synthesis,³ such as soraprazan, alpidem (a non-sedative anxiolytic),⁴ and zolpidem (a hypnotic drug).⁵ The exceptional promise of a broad therapeutic potential has drawn intense interest in developing concise approaches to synthesize substituted imidazo[1,2-*a*]pyridines. In the past several years, many well-documented modern methods had been developed for construction the scaffold of imidazo[1,2-*a*]pyridines.⁶ However, there are very few general methods that convert commercially available or readily accessible materials to substituted imidazo[1,2-*a*]pyridines with aldehyde group. Thus, the synthesis of substituted imidazo[1,2-*a*]pyridines preserving the aldehyde group under oxidative conditions remains a challenging work.

Direct C-H functionalization and C-N bond formation represent as the powerful and ideal approaches for the synthesis of various heterocyclic compounds.⁷ Especially, transition-metal catalyzed tandem reactions via direct C-H functionalization and C-N bond



Scheme 1. Strategies for the syntheses of imidazopyridines

formation as an active field of organic chemistry have been evolved as powerful tools to generate of heterocyclic compounds.⁸ Moreover, air as an ideal oxidant has drawn much attentions in for its abundance, environment-friendly and attractive industrial prospects.⁹ Recently, Yan's¹⁰ and Hajra's¹¹ group and our group had reported the direct method to synthesize substituted imidazopyridines (Scheme 1, eq.1-2). In 2011, Zhu and co-workers elegantly developed a direct methodology to formyl-substituted imidazo[1,2-*a*]pyridines via copper-catalyzed intramolecular dehydrogenative aminooxygenation in satisfactory to high yields (Scheme 1, eq.3).¹² Inspired by their works and some our previously studies about the synthesis of heterocyclic compounds,¹³ herein, we report a facial and direct method to synthesize formyl-substituted from aminopyridines and cinnamaldehydes via copper catalyst.


We first investigated the reaction of cinnamaldehyde (**1a**) and pyridin-2-amine (**2a**) in DMF at 100 °C with Cu-

L.-H. Zhai, L.-H. Guo, B.-W. Sun

^a School of Chemistry and Chemical Engineering, Southeast University, Nanjing, 211189, China. E-mail: chmsunbw@seu.edu.cn

^b Lunan Pharmaceutical Co. LTD, Linyi, 276000, Shandong, China.


Electronic Supplementary Information (ESI) available: Experimental procedures, spectroscopic data. See DOI: 10.1039/c000000x/

Table 1. Optimization of reaction condition ^a

entry	catalyst	additive	solvent	temp	yield
1	CuI		DMF	100	55
2	CuBr		DMF	100	21
3	CuCl		DMF	100	20
4	Cu(OAc) ₂		DMF	100	26
5	Cu(OTf) ₂		DMF	100	19
6	CuI		DMF	120	60
7	CuI	CF ₃ COOH (0.2)	DMF	120	68
8	CuI	TSOH (0.2)	DMF	120	43
9	CuI	PivOH (0.2)	DMF	120	70
9	CuI	PivOH (0.2)	DMSO	120	72
10	CuI	PivOH (0.2)	PhMe	reflux	-
11	CuI	PivOH (0.2)	CH ₃ CN	reflux	32
12	CuI	ZnCl ₂ (0.1)	DMSO	120	70
13	CuI	ZnCl ₂ (0.1)+1,10-phenanthroline (0.1)	DMSO	120	74
14	CuI	ZnCl ₂ (0.1)+TMEDA (0.1)	DMSO	120	63
15	CuI	ZnCl ₂ (0.1)+ Pyridine (0.1)	DMSO	120	80
16 ^c	CuI	ZnCl ₂ (0.1)+ Pyridine (0.1)	DMSO	120	62
17		ZnCl ₂ (0.1)+Pyridine (0.1)	DMSO	120	-

^a Reaction conditions: **1a** (0.3 mmol), **2a** (0.6 mmol), additive, solvent (2 mL), 8h. ^b Yields of isolated products. ^c The reaction was carried out under air. ^c Under O₂.

Table 2. Synthesis of substituted formyl-substituted imidazo[1,2-*a*]pyridines from aminopyridines and cinnamaldehydes^a




entry	R ¹	R ²	product	yields
1	1a	2a	3aa	80
2	1a	2b	3ab	32
3	1a	2c	3ac	42
4	1a	2d	3ad	trace
5	1a	2e	3ae	38
6	1a	2f	3af	52
7	1a	2g	3ag	88
8	1a	2h	3ah	79
9	1a	2i	3ai	95
10	1a	2j	3aj	78
11	1a	2k	3ak	52
12	1b	2a	3ba	66
13	1c	2a	3ca	44
14	1d	2a	3da	36
15	1e	2a	3ea	32
16	1f	2a	3fa	38
17	1b	2g	3bg	trace
18	1g	2a	3ga	-

catalysis. To our delight, an expected product of 2-phenylimidazo[1,2-*a*]pyridine-3-carbaldehyde (**3aa**) was isolated in 55% yield (Table 1, entry 1). Surprisingly, the aldehyde of cinnamaldehyde was preserved under the oxidative conditions. Substituted imidazo[1,2-*a*]pyridines with free intact formyl group can be easily converted to various functional groups and show enormous potential applications in organic synthesis.⁷ Encouraged by this interesting result, we screened copper catalysts to increase the yield of this transformation and CuI showed the highest activity for this reaction (Table 1, entry 2-5). Increasing temperature of reaction just slightly improved the yield (Table 1, entry 6). Then, the influencing parameters of additives, oxidants and solvents was evaluated, the use of ZnCl₂ and pyridine as additive led to a significant improvement and offered the target compound in 80% yield (Table 1, entry 15). Obviously, ZnCl₂ promotes the reaction by coordinating with the oxygen of aldehyde. Nevertheless, without copper salts as catalyst, no desired product was obtained (Table 1, entry 17).

With the optimized reaction conditions in hand, we extended the substrate scope of this reaction, and the results are illustrated in Table 2. Various aminopyridines with methyl,

methoxyl, cyano, fluoro, chloro, bromo, ester and benzyloxyl groups proceeded smoothly and generated the corresponding compounds successfully in moderate to good yields. As shown in Table 2, the results indicated that this transformation was sensitive to electronic effect of aminopyridines. The aminopyridines with the electron-drawing groups show better reactivity and gave the desired products in higher yields. Whereas, the electron-donating groups on aminopyridines significantly affected the efficiency of the process and resulted in lower yields (Table 2, entry 2-10). Further studies showed that a variety of substituted cinnamaldehydes successfully produced the desired products **3** with lower yields. Similarly, the electronic effect of cinnamaldehydes also affected this transformation obviously. The electron-rich cinnamaldehydes show better reactivity and gave higher yields than electron-deficient ones (Table 2, entry 12-16). Unfortunately, substituted pyrrole **3bg** was not achieved well by using **1b** and **2g** as substrate (Table 2, entry 17). Moreover, when (*E*)-but-2-enal **1g** and **2a** were subjected to the standard condition, no desired product was detected.



Scheme 2. Proposed mechanism

Based on the experimental results, we propose the reaction mechanism shown in Scheme 2. Firstly, cinnamaldehyde **1** and pyridin-2-amine **2** undergo Michael addition to form the intermediate **4**. Then, the radical cation **5**, which is generated by one electron oxidation, produces the nitrenium ion **6** by hydrogen abstraction with oxidation. Then imine **7** is formed by proton elimination from **6** and equilibrates to enamine **8**. Subsequently, enamine **8** would rearrange to the complex **9**, and complex **9** coordinates with the copper (II) catalyst to form the intermediate **10**.^{14,15} Finally, the target molecular **3aa** is afforded by reductive elimination of copper catalyst.

In conclusion, we have developed a Cu-catalyzed oxidative cyclization method with aminopyridines and cinnamaldehydes to form formyl-substituted imidazo[1,2-*a*]pyridines. In this transformation, the sensitive aldehyde group was preserved under oxidant conditions. This approach, in which the air was used as oxidant, provided a simple and practice method to synthesis the substituted formyl imidazo[1,2-*a*]pyridines.

This work is supported by National Natural Science Foundation of China (No. 21241009 and 21371031) and International S&T Cooperation Program of China (No. 2015DFG42240).

Notes and references

- (a) K. C. Rupert, J. R. Henry, J. H. Dodd, S. A. Wadsworth, D. E. Cavender, G. C. Olini, B. S. Fahmy, *J. Bioorg. Med. Chem. Lett.*, 2003, **13**, 347; (b) A. R. Katritzky, Y.-J. Xu, H. Tu, *J. Org. Chem.*, 2003, **68**, 4935; (c) Y. Katsura, S. Nishino, Y. Inoue, M. Tomoi, H. Takasugi, *Chem. Pharm. Bull.*, 1992, **40**, 371; (d) S. M. Hanson, E. V. Morlock, K. A. Satyshur, C. Czajkowski, *J. Med. Chem.*, 2008, **51**, 7243; (e) M. H. Wiegand, *Drugs* 2008, **68**, 2411.
- (a) Y. Katsura, S. Nishino, Y. Inoue, M. Tomoi, H. Takasugi, *Chem. Pharm. Bull.*, 1992, **40**, 371; (b) Y. Rival, G. Grassy, G. Michel, *Chem. Pharm. Bull.*, 1992, **40**, 1170; (c) K. C. Rupert, J. R. Henry, J. H. Dodd, S. A. Wadsworth, D. E. Cavender, G. C. Olini, B. Fahmy, J. J. Siekierka, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 347; (d) S. M. Hanson, E. V. Morlock, K. A. Satyshur, C. Czajkowski, *J. Med. Chem.*, 2008, **51**, 7243.
- (a) G. C. Moraski, L. D. Markley, P. A. Hipskind, H. Boshoff, S. Cho, S. G. Franzblau, M. J. Miller, *ACS Med. Chem. Lett.*, 2011, **2**, 466; (b) M. H. Wiegand, *Drugs* 2008, **68**, 2411.
- S. Z. Langer, S. Arbillá, J. Benavides, B. Scatton, *Adv. Biochem. Psychopharmacol.*, 1990, **46**, 61.
- T. S. Harrison, G. M. Keating, *CNS Drugs* 2005, **19**, 65.
- (a) A. J. Stasyuk, M. Banasiewicz, M. K. Cyranski, D. T. Gryko, *J. Org. Chem.*, 2012, **77**, 5552; (b) M. Adib, E. Sheikhi, N. Rezaei, *Tetrahedron Lett.*, 2011, **52**, 3191; (c) E. F. DiMauro, J. M. Kennedy, *J. Org. Chem.*, 2007, **72**, 1013; (d) K. Groebke, L. Weber, F. Mehlh, *Synlett* 1998, 661; (e) S. K. Guchhait, A. L. Chandgude, G. Priyadarshani, *J. Org. Chem.*, 2012, **77**, 4438; (f) P. Liu, L.-S. Fang, X. Lei, G.-Q. Lin, *Tetrahedron Lett.*, 2010, **51**, 4605; (g) N. Chernyak, V. Gevorgyan, *Angew. Chem.*, 2010, **122**, 2803; *Angew. Chem. Int. Ed.*, 2010, **49**, 2743; (h) Z.-J. Cai, S.-Y. Wang, S.-J. Ji, *Adv. Synth. Catal.*, 2013, **355**, 2686; (i) C. He, J. Hao, H. Xu, Y. Mo, H. Liu, J. Han, A. Lei, *Chem. Commun.*, 2012, **48**, 11073; (j) H. Wang, Y. Wang, C. Peng, J. Zhang, Q. Zhu, *J. Am. Chem. Soc.*, 2010, **132**, 13217; (k) K. S. Masters, T. R. M. Rauws, A. K. Yasav, W. A. Herrebout, B. V. Veken, B. U. W. Mases, *Chem. Eur. J.*, 2011, **17**, 6315; (l) I. R. Lahoz, C. Sicre, A. Navarro-Vazquez, C. S. Lopez, M. M. Cid, *Org. Lett.*, 2009, **11**, 4802; (m) L. Ma, X. Wang, W. Yu, B. Han, *Chem. Commun.*, 2011, **47**, 11333; (n) D. C. Mohan, R. R. Donthiri, S. N. Rao, S. Adimurthy, *Adv. Synth. Catal.*, 2013, **355**, 2217; (o) X. Wang, L. Ma, W. Yu, *Synthesis* 2011, **15**, 2445; (p) S. Santra, A. K. Bagdi, A. Majee, A. Hajra, *Adv. Synth. Catal.*, 2013, **355**, 1065; (q) A. K. Bagdi, M. Rahman, S. Santra, A. Majee, A. Hajra, *Adv. Synth. Catal.*, 2013, **355**, 1741.
- (a) S. R. Dubbaka, P. Vogel, *Angew. Chem. Int. Ed.*, 2005, **44**, 7674; (b) J. Q. Yu, Z. J. Shi, *C-H Activation*: Springer, Berlin, 2010; (c) D. A. Colby, R. G. Bergman, J. A. Ellman, *Chem. Rev.*, 2010, **110**, 624; (d) D. Alberico, M. E. Scott, M. Lautens, *Chem. Rev.*, 2007, **107**, 174; (e) Y. J. Park, J.-W. Park, C.-H. Jun, *Acc. Chem. Res.*, 2008, **41**, 222; (f) H. Li, Y. Li, X.-S. Zhang, K. Chen, X. Wang, Z.-J. Shi, *J. Am. Chem. Soc.*, 2011, **133**, 15244; (g) C.-L. Sun, B.-J. Li, Z.-J. Shi, *Chem. Rev.*, 2011, **111**, 1293; (h) D. A. Colby, R. G. Bergman, J. A. Ellman, *Chem. Rev.*, 2010, **110**, 624; (i) C. Coperet, *Chem. Rev.*, 2010, **110**, 656; (j) T. W. Lyons, M. S. Sanford, *Chem. Rev.*, 2010, **110**, 1147; (k) I. A. Mkhaldid, I. J. H. Barnard, T. B. Marder, J. M. Murphy, J. F. Hartwig, *Chem. Rev.*, 2010, **110**, 890; (l) K. M. Engle, T.-S. Mei, M. Wasa, J.-Q. Yu, *Acc. Chem. Res.*, 2012, **45**, 788. (m) W. Wang, X. Peng, X. Qin, X. Zhao, C. Ma, C.-H. Tung, Z. Xu, *J. Org. Chem.*, 2015, **80**, 2835. (n) X. Peng, W. Wang, C. Jiang, D. Sun, Z. Xu, C.-H. Tung, *Org. Lett.*, 2014, **16**, 5354.
- (a) C.-H. Jun, *Chem. Soc. Rev.*, 2004, **33**, 610; (b) A. E. Wendlandt, A. M. Suess, S. S. Stahl, *Angew. Chem. Int. Ed.*, 2011, **50**, 11062; (c) C. Liu, H. Zhang, W. Shi, A. Lei, *Chem. Rev.*, 2011, **111**, 1780; (d) A. N. Campbell, S. S. Stahl, *Acc. Chem. Res.*, 2012, **45**, 851; (e) J. Yu, H. Yang, Y. Jiang, H. Fu, *Chem. Eur. J.*, 2013, **19**, 4271.
- (a) A. E. Wendlandt, A. M. Suess, S. S. Stahl, *Angew. Chem., Int. Ed.*, 2011, **50**, 11062; (b) Z. Shi, Y. Cui, N. Jiao, *Org. Lett.*, 2010, **12**, 2908.
- (a) R.-L. Yan, J. Luo, C.-X. Wang, C.-W. Ma, G.-S. Huang, Y.-M. Liang, *J. Org. Chem.*, 2010, **75**, 5395; (b) H. Yan, R. Yan, S. Yang, X. Gao, Y. Wang, G. Hang, Y. Liang, *Chem. Asian. J.*, 2012, **7**, 2028.
- (a) K. Monir, A. K. Bagdi, S. Mishra, A. Majee, A. Hajra, *Adv. Synth. Catal.*, 2014, **356**, 1105; (b) R.-L. Yan, H. Yan, C. Ma, Z.-Y. Ren, X.-A. Gao, G.-S. Huang, Y.-M. Liang, *J. Org. Chem.*, 2012, **77**, 2024.
- H. Wang, Y. Wang, D. Liang, L. Liu, J. Zhang, Q. Zhu, *Angew. Chem.*, 2011, **123**, 5796; *Angew. Chem. Int. Ed.*, 2011, **50**, 5678.
- L.-H. Zhai, L.-H. G. Y.-H. Luo, Y. Yang, B.-W. Sun, *Org. Process Res. Dev.* 2015, **19**, 849.
- (a) G. Zhang, J. Miao, Y. Zhao, H. Ge, *Angew. Chem.*, 2012, **124**, 8443; *Angew. Chem. Int. Ed.*, 2012, **51**, 8318; (b) Y. Wei, I. Deb, N. Yoshikai, *J. Am. Chem. Soc.*, 2012, **134**, 9098; (c) Z. Shi, M. Suri, F. Glorius, *Angew. Chem.*, 2013, **124**, 2992; *Angew. Chem. Int. Ed.*, 2013, **52**, 4892.
- S. Ueda, H. Nagasawa, *J. Am. Chem. Soc.*, 2009, **131**, 15080.